6533b821fe1ef96bd127c32e
RESEARCH PRODUCT
Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms.
Antonio AgnelloJafar KargarSebastiano MercadanteCasuccio AlessandraSalvatore PumoSerena Garofalosubject
AdultMalemedicine.medical_specialtyPalliative careEpidemiologyAnalgesicPainOpioidAdverse effectPain ladderDiclofenacInternal medicineNeoplasmsMedicineHumansProspective StudiesCancer painAdverse effectNursing (all)2901 Nursing (miscellaneous)General NursingAgedAnalgesicsbusiness.industryAnti-Inflammatory Agents Non-SteroidalPalliative CareVisceral painMiddle AgedNSAIDVisceraAnesthesiology and Pain MedicineNeurologyOpioidAnesthesiaFemaleMechanismNeurology (clinical)medicine.symptombusinessCancer painmedicine.drugdescription
The role of nonsteroidal anti-inflammatory drugs (NSAIDs) is well established in the treatment of cancer pain. This class of drugs is considered particularly effective in pain due to somatic mechanisms, although proof of this observation is lacking. To ascertain whether NSAIDs are more effective in specific nociceptive forms of cancer pain, they were administered alone or added to opioids in 32 patients with a sole pain mechanism, somatic pain due to bone metastases (17 patients) or visceral pain (15 patients), respectively. Pain intensity, mean doses of opioids used, and symptoms were recorded after starting NSAID. A significant reduction in pain intensity was found at 3, 7, and 14 days. No differences in pain intensity between the two groups were observed. However, patients with a visceral mechanism required higher opioid doses after a week of treatment. No differences in adverse effects were reported. NSAIDs may be useful drugs in the management of cancer pain, regardless of the mechanism of pain involved. The incidence of adverse effects during prolonged administration should be assessed in future studies.
year | journal | country | edition | language |
---|---|---|---|---|
1999-05-01 | Journal of pain and symptom management |